Main Article Content
Objective: Many factors, including advanced age and female gender, have been identified as negative factors for peripheric blood hematopoietic stem cell (HSC) mobilization. Similarly, blood group antigens may have an effect on the release of HSCs from the bone marrow niche into the periphery. We aimed to study the effect of ABO and Rh blood groups on peripheral blood HSC mobilization in healthy donors.
Material and Method: The data of 314 healthy donors who underwent peripheric blood HSC mobilization in our center were analyzed retrospectively.
Results: The number of CD34+ cells collected on the first day and in total was the least in donors with blood group A. A statistically significant relation was found between ABO blood groups and the number of CD34+ cells collected on the first day and in total. No relation was found between Rh positivity and the number of CD34+ cells collected.
Conclusion: According to our research in the literature, this is the first study that investigates whether blood groups have an effect on the release of HSCs from the bone marrow niche into the periphery and we observed that blood group A is a negative risk factor for peripheric blood HSC mobilization.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
2. Storry JR, Olsson ML. The ABO blood group system revisited a review and update. Immunohematology. 2009; 25:48–59.
3. Schwarz HP, Dorner F. Karl Landsteine rand his major contributions to haematology. Br J Haematol. 2003; 121:556– 65.
4. Schulz C, von Andrian UH, Massberg S. Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue. Immunol Res. 2009;44 (1-3):160-68.
5. Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci. 2005;32(1):63-72.
6. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43(3):181–95.
7. Bonig H, Papayannopoulou T. Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Biol. 2012; 904:1–14.
8. Liu Y-F, Zhang S-Y, Chen Y-Y, Shi K, Zou B, Liu J, et al. ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence and Repopulation of Hematopoietic Stem Cells. Stem Cell Reports J. 2018; Vol. 11:258–73.
9. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89(7):2233–58.
10. Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004; 104:3091–6.
11. Kansas GS: Selectins and their ligands: Current concepts and controversies. Blood. 1996; 88: 3259-87.
12. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells: Pharmacol Rep. 2009; 61:22-32.
13. Carrasco Y.R, Fleire S.J, Cameron T, Dustin M.L, Batista F.D. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004; 20:589–599.
14. Van de Stolpe A and van der Saag PT: Intercellular adhesion molecule-1. J Mol Med (Berl). 1996; 74:13-33.
15. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 2008; 28:258–70.
16. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000; 95:3289–96.
17. Paré G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: Results of a genome-wide association study of 6,578 women. PLoS Genet. 2008; 4:e1000118.
18. Qi L, Cornelis MC, Kraft P, Jensen M, van Dam RM, Sun Q et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet. 2010; 19:1856-62.
19. Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010; 19:1863-72.
20. Otto VI, Damoc E, Cueni LN, Schürpf T, Frei R, Ali S et al. N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry. Glycobiology. 2006; 16:1033-44.
21. Martinez M, Joffraud M, Giraud S, Baïsse B, Bernimoulin MP, Schapira M. et al. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: Role of human fucosyltransferase-IV and -VII. J Biol Chem. 2005; 280: 5378-90.
22. Zhang W, Xu Q, Zhuang Y, CHEN Y. Novel association of soluble intercellular adhesion molecule 1 and soluble P-selectin with the ABO blood group in a Chinese population. Experimental and Therapeutic Medicine. 2016;12: 909-14.
23. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011;46(4):485–501.
24. Gratwohl A, Baldomero H, Schmid O, et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005; 36:575–90.
25. Lee SH, Lee MH, Lee JH, et al. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant. 2005;11(2):122–8.
26. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplantation. 1999;23:(Suppl. 2)29–33.
27. Takeyama K, Ohto H. PBSC mobilization. Transfus Apher Sci. 2004;31(3):233-43.
28. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-56.
29. Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005; 89(4):229–35.
30. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134(5):517–25.
31. Martino M, Bonizzoni E, Moscato T, Recchia AG, Fedele R, Gallo GA, et al. Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age. Biol Blood Marrow Transplant. 2015;21(5):881–8.
32. Anderlini P, Przepiorka D, Seong C, Smith TL, Huh YO, Lauppe J, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 1997;37(5):507–12.
33. De la Rubia J, Arbona C, de Arriba F, del Canizo C, Brunet S, Zamora C, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion. 2002; 42(1):4–9.
34. Ozkan MC, Sahin F, Saydam G. Peripheral blood stem cell mobilization from healthy donors. Transfus Apher Sci. 2015; 53(1):13–6.
35. Özkurt ZN, Batmaz L, Yeğin ZA, İlhan Ç. Factors affecting hematopoietic stem cell mobilization and apheresis in allogeneic donors: The role of iron status. Transfus Apher Sci. 2017; 56(3):470‐73.
36. Bertani G, Santoleri L, Martino M, et al. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. Transfusion. 2014;54(8):2028–33.
37. Motllo C, Sancho JM, Grifols JR, et al. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy. 2014;16(3):406–11.
38. Teipel R, Schetelig J, Kramer M, et al. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion 2015;55(12):2855–63..